Daily Chart

Send a Tweet

$NVS
#Novartis Ag-adr
NVS
Novartis Ag-adr
Look for:
NVS
Pre-Market Movers: $NVO,$FCL,$PCZ,$GSK,$ERTS,$HBC,$DDR,$DB,$GFA,$NVS...more
NVS
Novartis $NVS in-licenses a mid-to-late-stage experimental hepatitis C drug from a private Swiss co. Gains exclusive WW rights,except Japan.
NVS
Monday February 8 2010 MACD Sell Signal $ALXN $BAP $GILD $MCD $ROST $NVS $PETD $PII $LKFN $NTY #economics
NVS
@drpdtapp yes $NVS have Afinitor and $GSK have pazopanib. There are 6 approved in renal cc now
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. $RHHBY $NVS (@mhuckman)
NVS
Getting ready for exclusive interview w/Roche CEO Severin Schwan @ 7:30a ET-ish on Squawk Box. Crew tweaking lights now. $RHHBY $NVS
NVS
Allergan’s Looking Real Pretty Right Now http://cnbc.com/id/35238576 $ABT $ACL $AGN $NVS #StockPicks #StockMarket
NVS
RT@MhuckmanRoche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHH
NVS
Roche CEO Severin Schwan live 2mrw @ 7:30a ET-ish on "Squawk Box." 1st CNBC U.S. interview since buying Genentech. $RHHBY $NVS
NVS
Pfizer Earnings By the Numbers http://cnbc.com/id/35196988 $AMGN $BIIB $GENZ $GILD $MRK $NVS $PFE $WAT #StockMarket
NVS
$NVS $CSBTF Hypertension Market Will Be Constrained Through 2018 by Pipeline Containing Few Novel Emerging Therapies http://bit.ly/c3boXR
NVS
Is Genentech/Roche turning a blind eye to a marketing/PR opportunity for Lucentis/Avastin? Vote in the poll. http://bit.ly/9VSjxq $NVS
NVS
RT @adamfeuerstein: @mhuckman: Kaiser "real-world" study:Avastin = Lucentis for AMD. $NVS $RHHBY Genentech: Only L proven safe,eff
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
RT @mhuckman: Kaiser "real-world" study:Avastin works as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucent
NVS
BREAKING Kaiser "real-world" study:Avastin works just as well as Lucentis for AMD. $NVS $RHHBY Genentech:Only Lucentis proven safe
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
RT @mhuckman: FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.
NVS
FDA OKs using Glaxo's Tykerb w/Novartis' Femara for certain type advanced breast cancer in post-menopausal women. $GSK $NVS.




Novartis Ag-adr - NVS Insiders

No Insiders

We have no insiders for Novartis Ag-adr right now.

Know someone who is an insider on Novartis Ag-adr?
Let us know.

Novartis Ag-adr - NVS information

...
135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895
Last $93.56 USD
Change Today +0.38 / 0.41%
Volume 835.2K
As of 8:04 PM 09/29/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NVS) Snapshot

Open
$93.52
Previous Close
$93.18
Day High
$93.86
Day Low
$93.33
52 Week High
09/17/14 - $95.50
52 Week Low
10/10/13 - $72.77
Market Cap
253.2B
Average Volume 10 Days
1.5M
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
$2.76
Dividend Yield
2.95%
Request Investor Kit
NVS:US Advanced Stock Chart

novartis ag-adr (NVS) Related Bloomberg News

Actavis Blood Pressure Pill Not Backed by U.S. Advisers
Amazon, Oracle, Toshiba, Cipla: Intellectual Property
Fed Taper Question Keeps U.S. Corporate Bond Sales Below Average
Novartis Jury Awards $10.45 Million for Drug, Lawyer Says
Novartis’s Alcon Wins Bid to Block Apotex’s Generic Patanol

novartis ag-adr (NVS) Related News

Botox Maker Plans Deep Job Cuts During Takeover Fight
Who Should Pay the Bill for Wonder Drugs?
Big Pharma's Favorite Prescription: Higher Prices
Restrictions on Livestock Antibiotics Don't Worry the Drugmakers
[addPosition2]

novartis ag-adr (NVS) Key Developments

Novartis and University of Pennsylvania Establish New Centre for Car-Based Cancer Therapeutics

Novartis (Switzerland) and the University of Pennsylvania have unveiled plans to establish a Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus. The 30,000 square foot research facility focused on the development of chimeric antigen receptor (CAR) therapies. The CACT will be funded with a USD 20 million investment from Novartis, and is anticipated to employ 100 high specialized professionals including scientists and clinicians from Penn and Novartis to discover, develop and manufacture these personal therapies. The facility is expected to be completed in 2016, and will include additional space to technologically advanced rooms where patient's immune cells will be processed, as well as new functions for the space including vaccine development, assay development, and correlative studies of biospecimens to assess patients' response to treatment.

Novartis Presents Data from the Phase III LANTERN Trial

Novartis presented data from the Phase III LANTERN trial, at the European Respiratory Society (ERS) International Congress, showing the superiority of its once-daily Ultibro Breezhaler (indacaterol + glycopyrronium bromide) over twice-daily Seretide Accuhaler (salmeterol + fluticasone; SFC) in reducing exacerbations and improving lung function in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Specifically, the new data presented by the company demonstrate that Ultibro Breezhaler was associated with a significant reduction of 31% in the rate of moderate-to-severe exacerbations in comparison with SFC as well as showed that the drug significantly increased lung function compared with SFC following 26 weeks of treatment.

Novartis Presents Results of its PARADIGM-HF Trial

Novartis (NVS) has presented results of its PARADIGM-HF trial, demonstrating its investigational heart failure medicine, LCZ696, was superior to ACE-inhibitor enalapril on key endpoints in heart failure study. LCZ696 reduced the risk of death from cardiovascular causes by 20%, reduced heart failure hospitalizations by 21%, and reduced the risk of all-cause mortality by 16%. Overall there was a 20% risk reduction on the primary endpoint, a composite measure of CV death or heart failure hospitalization. Results were presented at the European Society of Cardiology congress and published in the New England Journal of Medicine. Novartis plans to file the New Drug Application for review with the US FDA by the end of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $93.56 USD +0.38

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $107.51 USD -0.87
Merck & Co Inc $59.41 USD +0.02
Pfizer Inc $29.77 USD +0.05
Roche Holding AG SFr.282.20 CHF +1.50
Procter & Gamble Co/The $84.44 USD -0.14
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.9x
Price/Sales 3.8x
Price/Book 3.2x
Price/Cash Flow 25.7x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Novartis Ag-adr - NVS news

3 Mega-Cap Dividend Stock Ideas

Quote:
Read article

US doctor pleads guilty in securities case

Keywords: US doctor pleads guilty in securities case, nvs, pe-and-hedgefunds
Quote:
Read article

Awaiting Novartis acquisition, biotech firm Proteon raises $15.2M

Quote:
Read article

Will Investors Regret Leaving The US?

Keywords: ETFs,Investing,Markets,Stocks,Business,Exchange-traded fund,Forbes,IShares,Research and Analysis,Shares outstanding,Trade
Quote:
Read article

LEAD 1-Nestlé porté par la croissance dans les pays émergents

Quote:
Read article

UPDATE 1-Vectura extends VR315 deal with Sandoz to new areas

Keywords: United States, Will Waterman
Quote:
Read article

Momenta's earnings rise on market grab from Sanofi

Quote:
Read article

[$$] Novartis' MS Pill Questioned by U.K. Regulator

Quote:
Read article

9 Swiss Stocks That May Be a Haven

Quote:
Read article

Advisers steer clients to safer havens in stormy market

Keywords: Greece, Italy, Switzerland, RichardSatran, S&P 500
Quote:
Read article

Vanda Pharmaceuticals reports loss

Quote:
Read article

Swiss stocks - Factors to watch on Aug 5

Quote:
Read article

FDA: Generic biotech drugs require paradigm shift

Keywords: Israel, United States, Michele Gershberg, Phil Berlowitz
Quote:
Read article

UPDATE 2-Vectura gets new U.S. partner for copy of lung drug

Keywords: United States, Andrew Callus
Quote:
Read article

UPDATE 1-Vectura strikes new U.S. deal for lung drug VR315

Keywords: United States
Quote:
Read article

UPDATE 1-Finnish drug maker Orion Q2 meets forecast

Keywords: Switzerland, Jane Merriman
Quote:
Read article

Vanda aims for Argentina

Quote:
Read article

Buyout firms to bid for GSK drugs portfolio-sources

Keywords: Britain, Jane Merriman
Quote:
Read article

PDL posts bigger 2Q profit on lower legal costs

Keywords: PDL posts bigger 2Q profit on lower legal costs, nvs,pdli, earnings
Quote:
Read article

Flu "super antibody" may bring universal shot closer

Quote:
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2011-2012.